Ohio dermatologist Matthew J. Zirwas, MD, offers his view on what step therapy would look like in patients with atopic dermatitis.
Ohio dermatologist Matthew J. Zirwas, MD, offers his view on what step therapy would look like in patients with atopic dermatitis.
Transcript
As new therapies come online, what sorts of concerns, if any, do you have about patient access and issues around prior authorization or maybe step therapy?
It is one of the things that I spend a lot of time thinking about. And I always put it in terms of, who deserves these medications, because whenever we look at them from a safety and efficacy perspective, 100% they are better than every other option for atopic dermatitis. They both work better and are safer.
Now, on the other hand, they are extremely expensive. So dupilumab is around $37,000 a year; I'm guessing that the new medications are going to be priced relatively similarly. And so the question becomes, who deserves these? And I think the payers have gotten it completely wrong here. So far, the step therapy for dupilumab has been primarily topical agents—tacrolimus, pimecrolimus and crisaborole—and the patients have to fail those. I've seen some requirements that patients have to have failed an off-label immunosuppressant, something like methotrexate or cyclosporine.
All of that is—I have no idea who told the insurers or the payers to use those steps because they’re just ridiculously stupid. The topicals literally cannot work. You cannot give patients enough topical to cover the body surface area that's involved. The oral immunosuppressants—no where near effective enough, way too dangerous, and not FDA approved [for atopic dermatitis].
The only step therapy that should be is, a patient should have to have had systemic steroids. So the only therapy that really makes sense [is] you need to have had a trial of systemic steroids to calm your disease down, and then, you know, be transitioned to a topical regimen. And I've not seen a set of criteria anywhere that require that patients have failed systemic steroids prior to going on to these biologics. That's really what step therapy should be is systemic steroids.
You know, they've needed those in the past, and really they've needed them more than once. The way that we really should be managing these patients, if they're a new patient, new to a dermatologist, it should be, "Here’s some oral steroid to calm your disease down. It's going to be a short course, a few weeks, and we're going to transition you to the topical therapy." If you then need systemic steroids again, that by definition means you're not adequately controlled by topical therapy, and therefore you now should be somebody who's a candidate for one of these biologics or oral medications.
So, to me, the rational step therapy is, has this person needed systemic steroids more than once? The other things don't make any sense, either from a patient safety perspective, a cost perspective, any perspective, and the number of patients I see who are on biologics, who are on dupilumab who've never been on a systemic steroid is incredible. And they shouldn't be, they really shouldn't be. Because if maybe you could just give them the 1 course of steroids, systemic steroids transitioned to the topicals, and they'd be okay. But they never got that trial. And they should have.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More